FINWIRES · TerminalLIVE
FINWIRES

Nxera Pharma Partner Neurocrine Biosciences Doses First Patient in Phase 2 Schizophrenia Study

By

Nxera Pharma (TYO:4565) said its partner Neurocrine Biosciences has dosed the first patient in a mid-stage trial of an experimental schizophrenia treatment, triggering a $22.5 million milestone payment to the Japanese drugmaker, according to a Monday filing on the Tokyo Stock Exchange.

The Phase 2 study will evaluate NBI-1117570, an oral dual muscarinic M1/M4 receptor agonist discovered by Nxera, in adults with schizophrenia requiring in-patient care. The payment will be booked as revenue in the first quarter of fiscal 2026, Nxera said.

The randomized, double-blind, placebo-controlled trial is expected to enroll about 120 patients. Its main goal is to measure changes in the Positive and Negative Syndrome Scale (PANSS) total score, a standard tool used to assess symptom severity, while also tracking safety and tolerability.

NBI-1117570 targets muscarinic acetylcholine receptors in the brain, with M1 linked to cognitive function and M4 associated with psychosis. The compound was developed using Nxera's NxWave drug discovery platform and is being advanced under a multi-program partnership with Neurocrine.

Related Articles

Asia

SEM Holdings Controlling Shareholder Sells 9% Stake in Business

SEM Holdings (HKG:9929) said its controlling shareholder Yao Capital sold a 9% stake in the business to HH RSV-MIM Holdings, according to a Hong Kong bourse filing Friday.Shares of the electrical and mechanical engineering services fell over 10% in morning trade Monday.Yao Capital disposed 180 million shares of the firm for $13.2 million, reducing its stake from 75% to 66%, SEM said.

$HKG:9929
Asia

Market Chatter: Singapore to Likely Adjust Monetary Policy Amid Recession Fears

Singapore is likely to tighten its monetary policy at its April 14 review, amid global recession fears, according to a report by Bloomberg News on Monday.Citing a survey in which 15 out of 18 economists expected the Monetary Authority of Singapore to tighten its policy, the report said that the country's reliance on imported energy exposes it to the crisis in the Middle East.With fuel, transport and electricity costs rising, businesses are likely to face higher input prices, the report added.The MAS is also expected to update its inflation outlook, with the Ministry of Trade slated to release its latest report on economic performance during the first quarter of the year on Tuesday, the report noted.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

$^STI
Asia

Litian Pictures to Raise HK$10 Million via Share Placement

Litian Pictures (HKG:9958) said it plans to place up to 68 million new shares at HK$0.156 apiece under its general mandate, raising net proceeds of about HK$10.3 million, according to an April 10 Hong Kong bourse filing.Shares of the film production company were down nearly 4% in late morning trade on Monday.The placing shares represent about 15.7% of the company's existing issued share capital.The placing price represents a discount of about 15% to the stock's last close and nearly 16.8% to the five-day average price, the filing said.Litian Pictures said net proceeds will be used for general working capital.

$HKG:9958